Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

f acute migraine.

-- Preclinical data were published in the October 17, 2007, issue of the

Journal of Neuroscience demonstrating that tezampanel may be effective

in reversing or preventing muscle spasticity and rigidity of spinal

ischemia. TorreyPines plans to initiate a Phase II clinical trial of

tezampanel for the treatment of muscle spasticity and rigidity

secondary to spinal cord trauma during the second half of 2008. This

will be the company's first clinical trial of tezampanel in a non-pain

indication.

-- TorreyPines initiated a Phase I maximum tolerated dose trial evaluating

NGX426, the oral prodrug of tezampanel. Dosing up to 150 mg has been

completed, and the study will continue to dose until either the maximum

tolerated dose is reached or up to a maximum of 210 mg. This clinical

trial is expected to be completed in the first half of 2008.

TorreyPines reported pharmacokinetic data from this clinical trial

showing that the area under the curve (AUC), which represents the total

amount of drug absorbed by the body, of a single, 80 mg, oral dose of

NGX426 is comparable to the AUC of a single, 40 mg, subcutaneous dose

of tezampanel.

-- A multiple dose Phase I clinical trial evaluating NGX267 was completed,

marking the third Phase I trial that demonstrated NGX267 is safe and

well tolerated. This multiple dose trial confirmed data from a

previous study in which statistically significant increases in salivary

flow were detected. TorreyPines initiated a Phase II clinical trial in

xerostomia, or dry mouth, secondary to Sjogren's syndrome in

March 2008.

Financial Results

Revenue for the three-month period ended December 31, 2007, was $2.5 million, compared to revenue of $2.5 million for the same period in 2006. Operating expenses for
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Quest Diagnostics Incorporated (NYSE: DGX ), the world,s ... the final results for its previously announced cash tender offer ... (the "Tender Cap") of its 5.125% Senior Notes due 2010 ... The terms and conditions of the tender offer are described ...
... /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), a biotechnology ... announced statistically significant results from an analysis of ... the BST-CarGel(R) randomized clinical trial. Specifically, statistically significant ... BST-CarGel treatment was found during analyses of tissues ...
... for Discovery and Validation of New Biomarker Panels ... Rules-Based Medicine, Incorporated (RBM), the world,s leading multiplexed ... the most comprehensive collection of quantitative immunoassays for ... drug and diagnostic development. The new service, DiscoveryMAP(TM) ...
Cached Biology Technology:Quest Diagnostics Announces Final Tender Offer Results 2Quest Diagnostics Announces Final Tender Offer Results 3BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device 2BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device 3BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device 4BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device 5Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
(Date:4/17/2014)... fragmentation of forests in the Amazon help create ... to rapid and widespread forest loss during drought ... findings show that forests in the Amazon could ... with forest fires lead to large-scale loss of ... assistant professor of geography, Penn State. , "We ...
(Date:4/17/2014)... have detected new early-warning signs of the potential loss ... far-reaching implications for the diagnosis and treatment of diabetic ... Americans. , "We had not expected to see such ... said Ann Elsner, professor and associate dean in the ... study. "We set out to study the early signs, ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Angeles, Calif., May 22, 2011Some men of African descent may ... to research conducted at the Keck School of Medicine of ... study, published in the journal Nature Genetics on ... in men of African descent, who tend to more susceptible ...
... Researchers from the Centers for Disease Control and ... to prion diseases, looking at hunting, venison consumption, and ... reported in animals. Three prion diseases in particular ... Creutzfeldt-Jakob disease (vCJD), and chronic wasting disease (CWD) ...
... forces that guide how cells migratehow they manage to get ... living body are poorly understood. Scientists at the Harvard School ... Catalonia (IBEC) have, for the first time, devised a way ... conclusion is that the cells fight it out, each pushing ...
Cached Biology News:USC research determines apparent genetic link to prostate cancer in African-American men 2CDC assesses potential human exposure to prion diseases 2CDC assesses potential human exposure to prion diseases 3The dance of the cells: A minuet or a mosh? 2The dance of the cells: A minuet or a mosh? 3
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
A431 cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
... Mutation Explorer processes up to 48 ... traces. Data input can be from either ... terminator or primer chemistries. The detection parameters ... analyst to analyst consistency. We have ...
Biology Products: